Your browser doesn't support javascript.
loading
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
Grünwald, V; Seidel, C; Fenner, M; Ganser, A; Busch, J; Weikert, S.
Affiliation
  • Grünwald V; Hannover Medical School, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany. Gruenwald.Viktor@MH-Hannover.de
Br J Cancer ; 105(11): 1635-9, 2011 Nov 22.
Article in En | MEDLINE | ID: mdl-22033275
ABSTRACT

BACKGROUND:

Treatment of everolimus-resistant disease remains largely undefined in metastatic renal cell carcinoma (mRCC). We report on 40 patients (pts) who receive systemic treatment after failure of everolimus. PATIENTS AND

METHODS:

Forty pts received sunitinib (n=19), sorafenib (n=8), dovitinib (n=10) or bevacizumab/interferon (n=3) after failure of everolimus. Median progression-free survival (PFS), overall survival (OS) and best tumour response (according to Response Evaluation Criteria In Solid Tumors) were analysed retrospectively. Kaplan-Meier, log-rank test and Cox regression analyses were used to estimate or predict OS and PFS.

RESULTS:

Treatment of everolimus-resistant disease was associated with a PFS of 5.5 months. (range 0.4-22.3) and an objective partial remission (PR) in 4 pts (10%) and stable disease (SD) in 22 pts (55%). In univariate analyses, first-line treatment with sorafenib was the only variable to correlate with a prolonged PFS of treatment in everolimus-resistant disease (P=0.036). However, its significance as a predictive marker for subsequent therapy could not be verified in multivariate analyses.

CONCLUSIONS:

Vascular endothelial growth factor targeted therapy shows promising activity in everolimus-resistant metastatic renal cancer and warrants further studies.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Benzenesulfonates / Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Vascular Endothelial Growth Factor A / Kidney Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2011 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Benzenesulfonates / Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Vascular Endothelial Growth Factor A / Kidney Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2011 Type: Article Affiliation country: Germany